TTM
$28.15
YoY change
+96.0%
5Y CAGR
+28.8%
Peak year (2025)
$22.95
Latest annual
$22.95
EPS (Diluted) history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $22.95
EPS (Diluted) growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +96.0%
EPS (Diluted) history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $22.95 | +96.0% | +$11.24 | ||
| 2024 | $11.71 | +101.9% | +$5.91 | ||
| 2023 | $5.80 | -11.7% | −$0.77 | ||
| 2022 | $6.57 | +12.3% | +$0.72 | ||
| 2021 | $5.85 | -9.6% | −$0.62 | ||
| 2020 | $6.47 | -25.5% | −$2.22 | ||
| 2019 | $8.69 | +177.6% | +$5.56 | ||
| 2018 | $3.13 | -1747.4% | +$3.32 | ||
| 2017 | −$0.19 | -107.6% | −$2.68 | ||
| 2016 | $2.49 | +14.2% | +$0.31 | ||
| 2015 | $2.18 | +1.4% | +$0.03 | ||
| 2014 | $2.15 | -48.7% | −$2.04 | ||
| 2013 | $4.19 | +17.4% | +$0.62 | ||
| 2012 | $3.57 | -8.5% | −$0.33 | ||
| 2011 | $3.90 | -14.8% | −$0.68 | ||
| 2010 | $4.58 | +16.2% | +$0.64 | ||
| 2009 | $3.94 | -308.5% | +$5.83 | ||
| 2008 | −$1.89 | -169.7% | −$4.60 | ||
| 2007 | $2.71 | +10.6% | +$0.26 | ||
| 2006 | $2.45 | +35.4% | +$0.64 | ||
| 2005 | $1.81 | +9.0% | +$0.15 | ||
| 2004 | $1.66 | -30.0% | −$0.71 | ||
| 2003 | $2.37 | -5.2% | −$0.13 | ||
| 2002 | $2.50 | -2.0% | −$0.05 | ||
| 2001 | $2.55 | -8.6% | −$0.24 | ||
| 2000 | $2.79 | +13.4% | +$0.33 | ||
| 1999 | $2.46 | +31.6% | +$0.59 | ||
| 1998 | $1.87 | -650.0% | +$2.21 | ||
| 1997 | −$0.34 | -125.0% | −$1.70 | ||
| 1996 | $1.36 | -32.7% | −$0.66 | ||
| 1995 | $2.02 | +82.0% | +$0.91 | ||
| 1994 | $1.11 | +177.5% | +$0.71 | ||
| 1993 | $0.40 | -34.4% | −$0.21 | ||
| 1992 | $0.61 | -46.0% | −$0.52 | ||
| 1991 | $1.13 | +15.3% | +$0.15 | ||
| 1990 | $0.98 | +22.5% | +$0.18 | ||
| 1989 | $0.80 | +19.4% | +$0.13 | ||
| 1988 | $0.67 | +19.6% | +$0.11 | ||
| 1987 | $0.56 | +9.8% | +$0.05 | ||
| 1986 | $0.51 | +8.5% | +$0.04 | ||
| 1985 | $0.47 | — | — |
- 2025$22.95+96.0%
- 2024$11.71+101.9%
- 2023$5.80-11.7%
- 2022$6.57+12.3%
- 2021$5.85-9.6%
- 2020$6.47-25.5%
- 2019$8.69+177.6%
- 2018$3.13-1747.4%
- 2017−$0.19-107.6%
- 2016$2.49+14.2%
- 2015$2.18+1.4%
- 2014$2.15-48.7%
- 2013$4.19+17.4%
- 2012$3.57-8.5%
- 2011$3.90-14.8%
- 2010$4.58+16.2%
- 2009$3.94-308.5%
- 2008−$1.89-169.7%
- 2007$2.71+10.6%
- 2006$2.45+35.4%
- 2005$1.81+9.0%
- 2004$1.66-30.0%
- 2003$2.37-5.2%
- 2002$2.50-2.0%
- 2001$2.55-8.6%
- 2000$2.79+13.4%
- 1999$2.46+31.6%
- 1998$1.87-650.0%
- 1997−$0.34-125.0%
- 1996$1.36-32.7%
- 1995$2.02+82.0%
- 1994$1.11+177.5%
- 1993$0.40-34.4%
- 1992$0.61-46.0%
- 1991$1.13+15.3%
- 1990$0.98+22.5%
- 1989$0.80+19.4%
- 1988$0.67+19.6%
- 1987$0.56+9.8%
- 1986$0.51+8.5%
- 1985$0.47—
EPS (Diluted) values are taken from Eli Lilly's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's current diluted EPS (TTM) is $28.15. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual diluted EPS for Eli Lilly (LLY) came in at $22.95 – surged 96.0% year-over-year.
Across 2020–2025 (5 years), Eli Lilly diluted EPS produced a CAGR of +28.8% – sustaining 2 straight years of year-over-year growth.
The highest annual diluted EPS of $22.95 was reported in 2025. The lowest in the available history was −$1.89 in 2008.
Eli Lilly EPS (Diluted) by Year
Eli Lilly EPS (Diluted) 2025: $22.95
2025's diluted EPS for Eli Lilly came in at $22.95, surged 96.0% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly EPS (Diluted) 2024: $11.71
Eli Lilly posted diluted EPS of $11.71 in 2024, surged 101.9% from 2023.
Eli Lilly EPS (Diluted) 2023: $5.80
In 2023, Eli Lilly reported diluted EPS of $5.80, declined 11.7% below 2022.
Eli Lilly EPS (Diluted) 2022: $6.57
Eli Lilly diluted EPS in 2022 was $6.57, grew 12.3% from 2021.
Eli Lilly EPS (Diluted) 2021: $5.85
Eli Lilly diluted EPS in 2021 was $5.85.
See more financial history for Eli Lilly (LLY). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Eli Lilly (LLY), ranked by their latest diluted EPS
| $17.74 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation